CNNM1: A Potential Drug Target and Biomarker for Cyclin and CBS Domain-Divalent Metal Cation Transport Mediation

Target Name: CNNM1

NCBI ID: G26507

CNNM1

CNNM1: A Potential Drug Target and Biomarker for Cyclin and CBS Domain-Divalent Metal Cation Transport Mediation

Introduction

Cyclin and CBS domain-divalent metal cation transport mediator 1 (CNNM1) is a protein that plays a crucial role in regulating metal homeostasis in various organisms, including humans. It is a key component of the cytoskeleton, which is responsible for the structural integrity and mechanical stability of cells. In recent years, the study of CNNM1 has gained significant interest due to its potential involvement in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

CNNM1 functions as a transporter for metal ions, including cations such as K+, Ca2+, and Mg2+. It is expressed in various tissues and cells throughout the body and is involved in regulating the levels of these ions in the cytosol. The cytoskeleton is a complex structure that is essential for cell shape, mechanical stability, and cytoskeleton-associated signaling pathways. Cyclin, a protein that plays a central role in regulating cell cycle progression, is a key component of the cytoskeleton. Therefore, it is not surprising that CNNM1 is involved in regulating cyclin levels in various organisms.

CNNM1 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, brain, and kidney. It is highly conserved across different species, with only minor differences in its sequence and structure. The protein has four known functions:

1.Regulation of cyclin levels: CNNM1 is involved in regulating the levels of cyclin in the cytosol. It does this by binding to the N-terminus of cyclin, where the cyclin-DNA binding module (CBDM) is located. This interaction between CNNM1 and cyclin allows CNNM1 to regulate the levels of cyclin in the cytosol, thereby affecting the cell cycle progression.

2.Cytoskeleton organization: CNNM1 is involved in the organization of the cytoskeleton by regulating the distribution of microtubules in the cytosol. It does this by interacting with the protein T-tubulin, which is a key component of the cytoskeleton.

3.Cell signaling pathways: CNNM1 is involved in various signaling pathways, including the regulation of cell growth, differentiation, and apoptosis. It does this by interacting with various signaling molecules, including TGF-β1, NF-kappa-B, and p53.

4.Apoptosis: CNNM1 is involved in the regulation of apoptosis, which is a critical cell death mechanism that helps maintain tissue homeostasis. It does this by interacting with the protein Bcl-2, which is involved in the regulation of apoptosis.

Drugs targeting CNNM1

The study of CNNM1 has gained significant interest in recent years, and several drugs have been shown to target its activity. Here are some examples:

1. Taxol: Taxol is an anti-cancer drug that is currently used to treat various cancers, including breast cancer and ovarian cancer. It works by inhibiting the activity of tubulin, which is a key component of the cytoskeleton. This inhibition of tubulin leads to the G1-phase of the cell cycle being blocked, which results in cell death. Taxol is a microtubule blocker, which inhibits the polymerization of spindle microtubules, thereby hindering spindle formation and ultimately causing cell division to cease..

2. Vemetaxel: Vemetaxel is another anti-cancer drug that is used to treat various cancers, including

Protein Name: Cyclin And CBS Domain Divalent Metal Cation Transport Mediator 1

Functions: Probable metal transporter

The "CNNM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNNM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets